TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 27400374
Drug: Celecoxib treatment
Normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Celecoxib treatment
Study: 10749783
Drug: Endotoxin (lowest
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endotoxin (lowest dose)
Study: 10749783
Drug: Endotoxin (highest
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endotoxin (highest dose)
Study: 1305043
Drug: Ukrain (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ukrain (2.5 to 25 mg per injection, intramuscularly or intravenously, every 1-5 days)
Study: 1305043
Drug: Ukrain (various
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ukrain (various dosing schedules and intervals)
Study: 3977491
Drug: 3 micrograms
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 micrograms of heat-inactivated hepatitis B vaccine
Study: 3977491
Drug: 27 micrograms
Approvals — FDA: no, EMA: no, PMDA: no
Description: 27 micrograms of heat-inactivated hepatitis B vaccine
Study: 23197572
Drug: Tadalafil (a
Normalized name: TADALAFIL (ADCIRCA) 20MG TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tadalafil (a phosphodiesterase 5A inhibitor), single dose
Study: 18091705
Drug: Interstitial magnetic
Normalized name: MAGNESIA
DrugBank: Magnesium oxide (DB01377)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Interstitial magnetic resonance lymphography (MRL) using subcutaneous gadobutrol (5 mL: 4.5 mL Gadobutrol + 0.5 mL lidocaine hydrochloride)
Study: 18091705
Drug: X-ray direct
Normalized name: lactose, x-ray exposed (1000 rad)
Approvals — FDA: no, EMA: no, PMDA: no
Description: X-ray direct lymphography (lipiodol administered after 7 days in 3 patients)
Study: 2799034
Drug: Pankreon 700
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pankreon 700 (17 tablets, 11.9 g pancreatin, 476,000 UFIP lipase)
Study: 2799034
Drug: Control (first
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (first week without treatment)
Study: 23427838
Drug: Hypnotic tape
Normalized name: Synotic
DrugBank: Fluocinolone acetonide (DB00591)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hypnotic tape intervention
Study: 9104618
Drug: Endonasal administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Endonasal administration of an IgA enriched preparation
Study: 27870712
Drug: Megestrol acetate
Normalized name: Megestrol Acetate
DrugBank: Megestrol (DB19378)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Megestrol acetate 160 mg/d
Study: 8478668
Drug: Megestrol acetate
Normalized name: Megestrol Acetate
DrugBank: Megestrol (DB19378)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Megestrol acetate 480 mg/d
Study: 8478668
Drug: Megestrol acetate
Normalized name: Megestrol Acetate
DrugBank: Megestrol (DB19378)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Megestrol acetate 1280 mg/d
Study: 9480997
Drug: both treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: both treatments
Study: 24763156
Drug: Yoga therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Yoga therapy intervention
Study: 12198052
Drug: Target-Controlled Infusion
Normalized name: Diphtheria toxin-il-3 fusion protein targeting IL-3 receptor
DrugBank: Tagraxofusp (DB14731)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Target-Controlled Infusion (TCI) of propofol (plasma target concentration, 2.5-3.5 micro g/mL; n = 20)
Study: 12198052
Drug: Manually-Controlled Infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Manually-Controlled Infusion (MCI) of propofol (3.0-4.0 mg.kg(‐1).h(‐1); n = 20)
Study: 2031196
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose tamoxifen, 150 mg/m2 orally daily for 6 months, then 50 mg/m2 until tumor progression (arm B)
Study: 16435471
Drug: ranitidine (320
Approvals — FDA: no, EMA: no, PMDA: no
Description: ranitidine (320 mg/day)
Study: 1459517
Drug: cimetidine (800
Approvals — FDA: no, EMA: no, PMDA: no
Description: cimetidine (800 mg/day)
Study: 2944380
Drug: ranitidine (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: ranitidine (150 mg twice daily)
Study: 28167545
Drug: MRX-I single
Normalized name: iobenguane I-131
Approvals — FDA: no, EMA: no, PMDA: no
Description: MRX-I single ascending doses under fasting or fed condition
Study: 28167545
Drug: MRX-I 800
Normalized name: MRX-I
DrugBank: MRX-I (DB12796)
Approvals — FDA: no, EMA: no, PMDA: no
Description: MRX-I 800 mg every 12 hours for 14 days
Study: 28167545
Drug: MRX-I 800
Normalized name: MRX-I
DrugBank: MRX-I (DB12796)
Approvals — FDA: no, EMA: no, PMDA: no
Description: MRX-I 800 mg every 12 hours for 28 days
Study: 21255957
Drug: RVX-208 (50,
Approvals — FDA: no, EMA: no, PMDA: no
Description: RVX-208 (50, 100, or 150 mg twice daily for 12 weeks)
Study: 19593886
Drug: Scheduled analgesia
Normalized name: Analgesic Balm GRX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Scheduled analgesia with lornoxicam (8 mg preoperatively, 8 mg after 6-8 hours, and 8 mg every 8 hours for 48 hours postoperatively)
Study: 11385269
Drug: rizatriptan 10-mg
Normalized name: rizatriptan 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: rizatriptan 10-mg
Study: 11576197
Drug: sumatriptan 50-mg
Normalized name: sumatriptan 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: sumatriptan 50-mg tablet
Study: 2874783
Drug: Epinephrine added
Normalized name: Epinephrine
DrugBank: Epinephrine (DB00668)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Epinephrine added to betaxolol treatment
Study: 2874783
Drug: Epinephrine added
Normalized name: Epinephrine
DrugBank: Epinephrine (DB00668)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Epinephrine added to timolol treatment
Study: 29853453
Drug: Placebo, administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo, administered for 24 weeks.
Study: 26711799
Drug: Conventional with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional with VT therapy ≥170 (Treatment arm A)
Study: 25330017
Drug: Ongoing buprenorphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ongoing buprenorphine maintenance therapy
Study: 25330017
Drug: Buprenorphine taper
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buprenorphine taper
Study: 23735180
Drug: Reference sirolimus
Normalized name: Sirolimus
DrugBank: Sirolimus (DB00877)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Reference sirolimus tablets
Study: 20619475
Drug: 360 microg
Normalized name: Interferon alfa-2a (as peginterferon alfa-2a) 360 microgram/mL solution for injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: 360 microg PEG‐IFNalpha‐2a weekly with RBV 1000‐1200 mg/day for 12 weeks followed by 36 weeks of 180 microg PEG‐IFNalpha‐2a weekly plus RBV 1000‐1200 mg/day
Study: 20619475
Drug: 180 microg
Normalized name: Pramipexole (as pramipexole dihydrochloride) 180 microgram oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 180 microg PEG‐IFNalpha‐2a weekly with RBV 1000‐1200 mg/day for 12 weeks followed by 36 weeks of 180 microg PEG‐IFNalpha‐2a weekly plus RBV 1000‐1200 mg/day
Study: 8852414
Drug: Oral B
Normalized name: bran ORAL BOX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral B subunit‐killed whole cell (BS‐WC) vaccine
Study: 8852414
Drug: Killed whole
Normalized name: Betula lenta whole
DrugBank: Betula lenta whole (DB14164)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Killed whole cell‐only (WC) vaccine
Study: 1737542
Drug: Subcutaneous intensive
Normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subcutaneous intensive insulin therapy (SC)
Study: 29777975
Drug: Bevacizumab +
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Bevacizumab + chemotherapy (BEV)
Study: 26914135
Drug: 75 mg
Normalized name: talc 75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 75 mg pregabalin per os (Group P75)
Study: 26914135
Drug: 150 mg
Normalized name: pectin 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 mg pregabalin per os (Group P150)
Study: 26914135
Drug: 300 mg
Normalized name: rutin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg pregabalin per os (Group P300)
Study: 24552826
Drug: Anabolic steroids
Normalized name: ANABOLIC STEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anabolic steroids combined with a daily high-protein, high-calorie diet
Study: 10581593
Drug: Standard protocol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard protocol (insulin clamp)
Study: 2912119
Drug: 0.5% balanced
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5% balanced salt solution (placebo)
Study: 23413998
Drug: Fluoxetine co-administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoxetine co-administration with clopidogrel
Study: 15182397
Drug: Phenolic-rich dessert
Normalized name: Phenol
DrugBank: Phenol (DB03255)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Phenolic-rich dessert (200 g daily for 2 weeks)
Study: 31233373
Drug: Compression therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Compression therapy using a sports bra of compression type for 9 months
Study: 25319385
Drug: Inappropriate antibiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inappropriate antibiotic therapy
Study: 18052559
Drug: Desvenlafaxine (100-200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Desvenlafaxine (100-200 mg/day)
Study: 17465457
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of EUS and MMP-9
Study: 15163163
Drug: Functional Assessment
Normalized name: plasma protein fraction Injection [Plasmanate]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Functional Assessment of Cancer Therapy Scale‐General (FACT‐G)
Study: 11310450
Drug: Freedom from
Approvals — FDA: no, EMA: no, PMDA: no
Description: Freedom from treatment failure (FFTF) for all patients with secondary NHL
Study: 11310450
Drug: Freedom from
Approvals — FDA: no, EMA: no, PMDA: no
Description: Freedom from treatment failure (FFTF) for patients with diffuse large-cell lymphoma
Study: 8198080
Drug: FR‐3 appliance
Approvals — FDA: no, EMA: no, PMDA: no
Description: FR‐3 appliance therapy
Study: 31124042
Drug: Vitamin D3
Normalized name: Vitamin D3
DrugBank: Cholecalciferol (DB00169)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D3 (2.5 mg or 100,000 IU)
Study: 24047486
Drug: Conventional medical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional medical therapy (CMT)
Study: 24928796
Drug: Oxybutynin 2.5
Normalized name: oxyBUTYnin 2.5 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxybutynin 2.5 mg
Study: 14671905
Drug: Isoflurane and
Normalized name: Isoflurane
DrugBank: Isoflurane (DB00753)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Isoflurane and intravenous bolus injections of fentanyl with epidural anesthesia by morphine at lumbar level
Study: 9215817
Drug: Megestrol acetate
Normalized name: Megestrol Acetate
DrugBank: Megestrol (DB19378)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Megestrol acetate (MA) 40 mg four times daily
Study: 9367070
Drug: Oral retinol
Normalized name: retinol
DrugBank: Vitamin A (DB00162)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral retinol (25,000 units)
Study: 9367070
Drug: Isotretinoin (5-10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isotretinoin (5-10 mg)
Study: 31584684
Drug: Intervention group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intervention group (30% decrease in daily rates) for MRSA bacteremia
Study: 31584684
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (30% decrease in daily rates) for MRSA bacteremia
Study: 31584684
Drug: Intervention group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intervention group (30% decrease in daily rates) for CAUTI
Study: 31584684
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (30% decrease in daily rates) for CAUTI
Study: 31584684
Drug: Intervention group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intervention group (30% decrease in daily rates) for CLABSI
Study: 31584684
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (30% decrease in daily rates) for CLABSI
Study: 31584684
Drug: Intervention group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intervention group (30% decrease in daily rates) for CDI
Study: 31584684
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (30% decrease in daily rates) for CDI
Study: 29972861
Drug: Intravenous fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intravenous fentanyl and No fentanyl
Study: 15705120
Drug: venlafaxine XR
Normalized name: venlafaxine Extended Release Oral Capsule
DrugBank: Venlafaxine (DB00285)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: venlafaxine XR 75 mg
Study: 15705120
Drug: venlafaxine XR
Normalized name: venlafaxine Extended Release Oral Capsule
DrugBank: Venlafaxine (DB00285)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: venlafaxine XR 150 mg
Study: 12011124
Drug: ACVBP chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ACVBP chemotherapy
Study: 16432076
Drug: High-dose therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose therapy (HDT)
Study: 7672654
Drug: Nafarelin acetate,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nafarelin acetate, administered pre-operatively for three months
Study: 31553834
Drug: Vedolizumab (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vedolizumab (300 mg infusion on day 1 and at weeks 2, 6, 14, 22, 30, 38, and 46)
Study: 31553834
Drug: Vedolizumab (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vedolizumab (300 mg infusion)
Study: 31553834
Drug: Adalimumab (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adalimumab (40 mg subcutaneous injection at week 1, 80 mg at week 2, and 40 mg every 2 weeks thereafter)
Study: 31553834
Drug: Adalimumab (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adalimumab (40 mg subcutaneous injection)
Study: 28915826
Drug: HuoXueSanFeng acupuncture
Approvals — FDA: no, EMA: no, PMDA: no
Description: HuoXueSanFeng acupuncture combined with one antihypertensive medication
Study: 11141029
Drug: Presurgical infant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Presurgical infant orthopedic treatment (PIO) during the first year of life
Study: 22538118
Drug: Ginger (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ginger (2 g ginger powder in hot water)
Study: 2104627
Drug: Enalapril (ACE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enalapril (ACE inhibitor) for 30 days
Study: 211983
Drug: Fluphenazine enanthate
Normalized name: Fluphenazine Enanthate
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fluphenazine enanthate low-dose (0.25 ml) with family therapy
Study: 19223643
Drug: IDX899 50
Approvals — FDA: no, EMA: no, PMDA: no
Description: IDX899 50 mg capsule
Study: 19223643
Drug: IDX899 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: IDX899 200 mg capsule
Study: 19223643
Drug: IDX899 800
Approvals — FDA: no, EMA: no, PMDA: no
Description: IDX899 800 mg once daily (QD)
Study: 19223643
Drug: IDX899 400
Approvals — FDA: no, EMA: no, PMDA: no
Description: IDX899 400 mg twice daily (BID)
Study: 6476557
Drug: New cardiopulmonary-cerebral
Normalized name: Sus scrofa cerebral cortex preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: New cardiopulmonary-cerebral resuscitation therapies
Study: 24588932
Drug: Multispecies probiotic
Normalized name: Rezyst Probiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multispecies probiotic (6 different probiotic strains; 10^9 cfu/g) for 6 weeks
Study: 11020745
Drug: Epinephrine test
Normalized name: Epinephrine
DrugBank: Epinephrine (DB00668)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Epinephrine test dose
Study: 11020745
Drug: Isoproterenol test
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isoproterenol test dose
Study: 1972927
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg astemizole
Study: 1510286
Drug: 30 mg
Normalized name: agar 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg astemizole
Study: 6426893
Drug: Standard intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard intravenous fluids (carbohydrates and amino acids)
Study: 31061014
Drug: Experimental treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Experimental treatment (psychosocial intervention administered by speech and language therapists)
Study: 16882684
Drug: Intranasal lidocaine
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intranasal lidocaine 8% spray
Study: 16882684
Drug: Saline placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline placebo spray
Study: 11512528
Drug: clarithromycin MR
Normalized name: Clarithromycin
DrugBank: Clarithromycin (DB01211)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: clarithromycin MR 500 mg once daily
Study: 8112370
Drug: Entacapone (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Entacapone (200 mg oral dose)
Study: 18661769
Drug: Acetaminophen (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetaminophen (10 mg/kg) along with DTP vaccine
Study: 18661769
Drug: Acetaminophen (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetaminophen (10 mg/kg) 2 hours after vaccination
Study: 18661769
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (acetaminophen after febrile reactions or irritability)
Study: 9845865
Drug: Outpatient drug-free
Approvals — FDA: no, EMA: no, PMDA: no
Description: Outpatient drug-free programs
Study: 8591712
Drug: Pravastatin (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pravastatin (20 mg daily for 12 weeks)
Study: 2612542
Drug: Intramuscular midazolam
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intramuscular midazolam at 0.15 mg.kg‐1
Study: 2612542
Drug: Rectal midazolam
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Rectal midazolam at 0.15 mg.kg‐1
Study: 2612542
Drug: Oral midazolam
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oral midazolam at 1 mg.kg‐1
Study: 1037281
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg mefexamide
Study: 1037281
Drug: 400 mg
Normalized name: mesna 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg mefexamide
Study: 31622885
Drug: Allogeneic PRP
Normalized name: allogeneic processed thymus tissue Drug Implant [Rethymic]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Allogeneic PRP treatment
Study: 31438858
Drug: Intracoronary infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intracoronary infusion of autologous bone marrow mononuclear cells (BMMNCs)
Study: 28786105
Drug: Low-dose 13-cis
Normalized name: 13-cis-retinoic acid
DrugBank: Isotretinoin (DB00982)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Low-dose 13-cis retinoic acid (7.5 mg or 10 mg) for 2 years
Study: 26418022
Drug: ivabradine 7.5
Normalized name: ivabradine 7.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: ivabradine 7.5 mg BID
Study: 21788309
Drug: PIEB (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: PIEB (10 mL every hour beginning 60 minutes after the initial dose)
Study: 21788309
Drug: CEI (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: CEI (10 mL/h, beginning immediately after the initial dose)
Study: 17088770
Drug: Auto-cross-linked hyaluronic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Auto-cross-linked hyaluronic acid gel (group A, 30 patients)
Study: 10997402
Drug: Three-times-daily indinavir
Normalized name: bupropion
DrugBank: Bupropion (DB01156)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Three-times-daily indinavir (800 mg every 8 h or 1200 mg every 12 h) with zidovudine (300 mg) and lamivudine (150 mg) every 12 h
Study: 10997402
Drug: Two-times-daily indinavir
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two-times-daily indinavir (800 mg every 8 h, 1000 mg every 12 h, or 1200 mg every 12 h) with zidovudine (300 mg) and lamivudine (150 mg) every 12 h
Study: 1591370
Drug: Protein A
Normalized name: Protein antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Protein A perfusion in cancer chemotherapy-related hemolytic-uremic syndrome
Study: 4054140
Drug: Nifedipine 20
Normalized name: nifedipine 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nifedipine 20 mg TID for 1 week
Study: 4054140
Drug: Prazosin 1
Normalized name: prazosin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prazosin 1 mg TID for 1 week
Study: 23904009
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment (N=13)
Study: 21396214
Drug: Oral amoxicillin/clavulanate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral amoxicillin/clavulanate 30 min before bronchoscopy
Study: 14749008
Drug: Hypothermia group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypothermia group (HG); rectal temperature = 34.5 degrees C +/‐ 0.3 degrees C, nasopharyngeal temperature = 34.0 degrees C +/‐ 0.5 degrees C, n = 23
Study: 6150050
Drug: C6/36 sham
Approvals — FDA: no, EMA: no, PMDA: no
Description: C6/36 sham vaccine (intraderma tests)
Study: 3927959
Drug: Nicardipine 120
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicardipine 120 mg day-1
Study: 22490629
Drug: Intensive antiplatelet
Normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive antiplatelet therapy
Study: 16339055
Drug: Multivitamin supplements
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multivitamin supplements
Study: 20536472
Drug: Synthetic thymosin
Normalized name: Synthetic camphor
DrugBank: Synthetic camphor (DB14156)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Synthetic thymosin beta4 (Tbeta4) 42-1260 mg, administered intravenously, single dose and daily for 14 days
Study: 10839287
Drug: DBPT chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: DBPT chemotherapy (dacarbazine, BCNU, cisplatin, and tamoxifen)
Study: 10839287
Drug: DTIC chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: DTIC chemotherapy
Study: 8971427
Drug: Captopril (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Captopril (2 x 25 mg day‐1)
Study: 8971427
Drug: Acetylsalicylic acid
Normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Acetylsalicylic acid (ASA) (1 x 100 mg day‐1)